Read our COVID-19 research and news.

This special feature is brought to you by the Science/AAAS Custom Publishing Office

New Product

SARS-CoV-2 Monoclonal Antibodies

For info: +44-(0)-1865-595230
The Native Antigen Company

The Native Antigen Company introduces 10 new monoclonal antibodies recognizing SARS-CoV-2, the causative agent of COVID-19. These antibodies recognize different epitopes of the SARS-CoV-2 spike glycoprotein, nine of which are SARS-CoV-2 specific and do not cross-react with other human coronaviruses; they extend our existing range and offer researchers a source of high-quality reagents for R&D of in vitro diagnostics, therapeutics, and vaccines for COVID-19. The SARS-CoV-2 antibodies were raised using our own S1 and S2 recombinant spike proteins as immunogens. Produced using our proprietary mammalian expression system, these antigens exhibit full glycosylation and proper folding to ensure that antibodies raised against them are highly specific. The antibodies have been screened against our other coronavirus proteins, including SARS, MERS, NL63, OC43, 229E, and HKU1, to demonstrate specificity. Three of the antibodies have been shown to be specific for the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2 bound to the cellular angiotensin-converting enzyme 2 (ACE2) receptor.

Custom Publishing

Read all of the best Custom Publishing content from Science. Visit our Custom Publishing section for special collections, tech features, posters and more.

Custom Publishing